S-Trityl-L-cysteine

S-Trityl-L-cysteine (NSC 83265) is a selective and allosteric kinesin Eg5 inhibitor with an IC50 of 1 μM for the inhibition of basal ATPase activity and 140 nM for the microtubule-activated ATPase activity. S-Trityl-L-cysteine has antitumor activities[1][2].

Product Specifications

CAS Number

[2799-07-7]

Product Name Alternative

NSC 83265; S-Tritylcysteine; 3-Tritylthio-L-alanine

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Kinesin

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/s-trityl-l-cysteine.html

Purity

99.53

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

N[C@@H](CSC(C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)C(O)=O

Molecular Formula

C22H21NO2S

Molecular Weight

363.47

Precautions

H302, H315, H319, H335

References & Citations

[1]Wei Wu, et al. S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma. Oncol Lett. 2018 Jul;16 (1) :1023-1030. |[2]Salvatore DeBonis, et al. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol Cancer Ther. 2004 Sep;3 (9) :1079-90.